1. A phase 2, randomized, double‐blind, multicenter study comparing siltuximab plus best supportive care (BSC) with placebo plus BSC in anemic patients with International Prognostic Scoring System low‐ or intermediate‐1–risk myelodysplastic syndrome. Issue 9 (23rd June 2014) Authors: Garcia‐Manero, Guillermo; Gartenberg, Gary; Steensma, David P.; Schipperus, Martin R.; Breems, Dimitri A.; de Paz, Raquel; Valcárcel, David; Kranenburg, Britte; Reddy, Manjula; Komrokji, Rami S. Journal: American journal of hematology Issue: Volume 89:Issue 9(2014:Sep.) Page Start: E156 Record Type: Journal Article View Content: Available online (eLD content is only available in our Reading Rooms) ↗